Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...

Pharmacodynamic Models: Overview

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting the Carotid Body Function With Big-K<sup>+</sup>-Channel Blocker ENA-001 in Opioid-Induced Respiratory Depression: A Scoping Review.

Pharmacology research & perspectives·2026

Same author

Effects of Selective Sphingosine-1-Phosphate Receptor 1 Agonist, TRV045, on Evoked Pain Tests: An Exploratory, Four-Way Cross-Over Study in Healthy Volunteers.

European journal of pain (London, England)·2026

Same author

Combination of the BK-Channel Antagonist ENA-001 and Naloxone Is More Effective Than Either Agent Alone in Reversing Fentanyl-Induced Respiratory Suppression in Rats.

Cureus·2026

Same author

Corrigendum to 'Morphine and hydromorphone pharmacodynamics in human volunteers: population-based modelling of interindividual response variability and utility' (Br J Anaesth 2026; 136: 1459-71).

British journal of anaesthesia·2026

Same author

Factors Associated With Concurrent Benzodiazepine and Opioid Use Following Total Hip and Knee Arthroplasty: A Nationwide Cohort Study.

Pharmacoepidemiology and drug safety·2026

Same author

<i>In Vivo</i> Detection of Nitrous Oxide in Blood and Saliva Following Recreational Use.

ACS omega·2026

Search research articles

Related Experiment Video

Updated: May 16, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

Translational PK-PD modeling in pain.

Ashraf Yassen¹, Paul Passier, Yasuhisa Furuichi

¹Global Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Europe, Elisabethhof 1, PO BOX 108, 2350 AC, Leiderdorp, The Netherlands. ashraf.yassen@astellas.com

Journal of Pharmacokinetics and Pharmacodynamics

|December 1, 2012

Summary

Translational pharmacokinetic-pharmacodynamic (PK-PD) modeling faces challenges due to limitations in animal pain models and the complexity of human pain. Utilizing PK-PD modeling with biomarkers in early clinical trials can bridge this gap for analgesic drug development.

More Related Videos

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies

Published on: October 6, 2022

Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model

Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model

Published on: September 1, 2023

Related Experiment Videos

Last Updated: May 16, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies

Published on: October 6, 2022

Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model

Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model

Published on: September 1, 2023

Area of Science:

Pharmacology
Translational Medicine
Pain Research

Background:

Translational pharmacokinetic-pharmacodynamic (PK-PD) modeling for analgesic drug development is hindered by poor predictive validity of animal pain models and the complex, multidimensional nature of human pain.
These limitations complicate the extrapolation of preclinical PK-PD data to clinical doses, resulting in a low success rate for drug targets identified in animal studies.

Purpose of the Study:

To explore the application of PK-PD modeling with biomarkers in early clinical development to bridge the gap between animal research and clinical pain studies.
To enhance the success of analgesic drug development, particularly for novel mechanisms of action, by understanding target pharmacology and linking it to clinical outcomes.
To investigate the use of human pain models as a link between preclinical and clinical research and to optimize dose selection for proof-of-concept studies.

Main Methods:

PK-PD modeling of biomarkers from early-phase clinical development.
Utilizing human pain models that mimic acute/chronic pain symptoms.
Characterizing the relationship between target site binding and downstream biomarkers in human studies.

Main Results:

PK-PD modeling of biomarkers can effectively link animal and clinical pain research.
Human pain models serve as a crucial bridge between preclinical findings and clinical application.
Early PK-PD modeling facilitates dose selection for proof-of-concept studies by linking target engagement to potential clinical endpoints.

Conclusions:

PK-PD modeling, especially when integrated with biomarker data and human pain models in early development, is essential for successful analgesic drug translation.
Understanding target pharmacology through PK-PD analysis is critical for novel analgesic mechanisms.
In patient studies, PK-PD modeling helps identify responder profiles to optimize dosing strategies, ensuring the right dose is administered to the right patient.